GlassScriptPhysician profile
Jill A Bennett
NPI 1851317051
$489.25
in general payments reported to CMS, 2019-2025
13 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $71.28 · 2024: $139 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.25 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $52.13 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $51.15 | 2024 | Trintellix |
| Abbvie INC. | $50.20 | 2024-2025 | |
| Abbott Laboratories | $47.52 | 2025 | |
| Lilly USA, LLC | $45.00 | 2025 | |
| Pfizer INC. | $42.67 | 2025 | |
| Sanofi Pasteur INC. | $42.43 | 2025 | |
| Novo Nordisk INC | $41.36 | 2023 | Wegovy |
| Viatris Specialty LLC | $38.70 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $29.41 | 2025 | Rexulti |
| Lundbeck LLC | $20.76 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.84 | 2025 | Jardiance |
| Exact Sciences Corporation | $13.08 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.